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Angiotensin (Ang)-(1–7) is now recognized as a biologically active component of the renin-angiotensin system (RAS). The
discovery of the angiotensin-converting enzyme homologue ACE2 revealed important metabolic pathways involved in the Ang-
(1–7) synthesis. This enzyme can form Ang-(1–7) from Ang II or less eﬃciently through hydrolysis of Ang I to Ang-(1–9) with
subsequent Ang-(1–7) formation. Additionally, it is well established that the G protein-coupled receptor Mas is a functional ligand
site for Ang-(1–7). The axis formed by ACE2/Ang-(1–7)/Mas represents an endogenous counter regulatory pathway within the
RAS whose actions are opposite to the vasoconstrictor/proliferative arm of the RAS constituted by ACE/Ang II/AT1 receptor. In
this review we will discuss recent ﬁndings concerning the biological role of the ACE2/Ang-(1–7)/Mas arm in the cardiovascular
and pulmonary system. Also, we will highlight the initiatives to develop potential therapeutic strategies based on this axis.
1.Introduction
The renin-angiotensin system (RAS) plays a key role in
several target organs, such as heart, blood vessels, and lungs,
exerting a powerful control in the maintenance of the home-
ostasis[1–4].Thissystemisactivatedbytheconversionofthe
angiotensinogen to the inactive peptide angiotensin (Ang) I
through the renin action [5]. Subsequently, Ang I is cleaved
by the angiotensin-converting enzyme (ACE) generating
Ang II [6], the main angiotensin peptide, whose actions
are mediated by two G protein-coupled receptors (GPCR),
AT1 and AT2 [7, 8]( Figure 1). The major physiological
functions of Ang II are mediated by AT1 receptor [9, 10]. In
pathological conditions, activation of this receptor induces
deleterious eﬀects, such as vasoconstriction, ﬁbrosis, cellular
growth and migration, and ﬂuid retention [11, 12]. On the
other hand, Ang II binding to the AT2 receptor generally
causes opposite eﬀects when compared with those actions
mediated by the AT1 receptor [13, 14].
Recently, it has been proposed that, in addition to the
ACE/Ang II/AT1 receptor axis, the RAS possesses a counter
regulatory axis composed by ACE2, Ang-(1–7), and Mas
receptor (Figure 1). Ang-(1–7) is a biologically active com-
ponent of the RAS which binds to Mas inducing many
beneﬁcial actions, such as vasodilatation, antiﬁbrosis, and
antihypertrophic and antiproliferative eﬀects [15–23]. This
peptide is produced mainly through the action of ACE2,
which has approximately 400-fold less aﬃnity to Ang I than
to Ang II [24–26]; thereby, Ang II is the major substrate
for Ang-(1–7) synthesis. In fact, the conversion of Ang II to2 International Journal of Hypertension
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Figure 1: Schematic representation of the renin-angiotensin system (RAS) cascade. The counterregulatory axes of the RAS are composed by
ACE/Ang II/AT1 and ACE2/Ang-(1–7)/Mas. ACE: angiotensin-converting enzyme; Ang: angiotensin; AT1:A n gI It y p e1r e c e p t o r ;A T 2:A n g
II type 2 receptor; Mas: Ang-(1–7) receptor; PCP: prolylcarboxypeptidase; PEP: prolyl-endopeptidase; NEP: neutral-endopeptidase 24.11.
Ang-(1–7) by ACE2 is important to regulate the RAS activity
since Ang-(1–7) induces opposite eﬀects to those elicited by
Ang II [16–24]. Additionally, ACE2 can form Ang-(1–7) less
eﬃciently through hydrolysis of Ang I to Ang-(1–9) with
subsequent Ang-(1–7) formation [24].
The relevance of the RAS is highlighted by the success
obtained in therapeutic strategies based on the pharma-
cological inhibition of this system in cardiovascular and
respiratory diseases [27–32]. Blockade of the RAS with
ACE inhibitors (ACEi) or AT1 receptor antagonists (ARBs)
improves the outcomes of patients with hypertension, acute
myocardial infarction, and chronic systolic heart failure [33–
35]. Furthermore, based on the involvement of the ACE/Ang
II/AT1 axis in respiratory diseases and the crucial role of the
lungs in the RAS metabolism, several studies have reported
the contribution of the RAS in lung pathophysiology [28, 30,
31, 36–40]. Importantly, it has been shown that administra-
tion of ACEi and ARBs causessubstantial increases in plasma
Ang-(1–7) levels, leading to the assumption that part of their
clinical eﬀects might be mediated by this heptapeptide [41–
43]. Indeed, some eﬀects of ACEi and ARBs can be blocked
or attenuated by A-779, a Mas antagonist, conﬁrming the
role of Ang-(1–7) in the actions of these compounds [44].
The beneﬁcial eﬀects of Ang-(1–7), as well as its likely
participation in the eﬀects of the ACEi and ARBs, represent
evidences for the potential of the ACE2/Ang-(1-7)/Mas axis
as a therapeutic target.
In this review, we will focus on the recent ﬁndings related
to the pathophysiology actions of the ACE2/Ang-(1–7)/Mas
axis in the cardiovascular and respiratory system. Also,
we will discuss the promising initiatives to develop new
therapeutic strategies based on this axis to treat pathological
conditions.
2.CardiacACE2/Ang-(1–7)/MasAxis
The heart is one of the most important targets for the
actions of the ACE2/Ang-(1–7)/Mas axis. In the heart, ACE2International Journal of Hypertension 3
is expressed in the endothelium [45], myoﬁbroblasts [46],
cardiomyocytes, and ﬁbroblasts [47, 48]. Classical pharma-
cotherapeutic agents used to treat heart failure, including
ACEi, ARBs, and aldosterone receptor blockers, increase
ACE2activityand/orexpression,indicatingitsimportancein
the cardiac diseases establishment and progression [49–51].
Additionally, pharmacological and genetic (transgenic
animals and gene transfer) approaches have evidenced the
signiﬁcance of ACE2 in cardiac pathologies. Despite some
controversies concerning the consequences of the ACE2
deﬁciency, in general, evidences indicate a protective role of
ACE2 in the heart [48, 52–57]. Crackower and colleagues
[52] were the ﬁrst to demonstrate that genetic ablation of
ACE2 results in severe blood-pressure-independent systolic
impairment. Also, disruption of ACE2 was able to accelerate
cardiac hypertrophy and shortened the transition period to
heart failure in response to pressure overload by increasing
localAngII[54].Recently,ithasbeendemonstratedthatloss
ofACE2enhancesthesusceptibilitytomyocardialinfarction,
with increased mortality, infarct expansion and adverse
ventricular remodeling [56]. In keeping with these genetic
ﬁndings, pharmacological inhibition of ACE2 exacerbated
cardiac hypertrophy and ﬁbrosis in Ren-2 hypertensive
rats [58]. On the other hand, cardiac overexpression of
ACE2 prevented hypertension-induced cardiac hypertrophy
and ﬁbrosis in spontaneously hypertensive rats (SHR) and
in Ang-II-infused rats [59, 60]. Indeed, transfection of
Lenti-ACE2 (lentivirus containing ACE2 cDNA) or Ad-
ACE2 (recombinant adenovirus carrying the murine ACE2)
into the surrounding area of the infarcted myocardium
was protective against pathological remodeling and cardiac
systolic dysfunction in a rat model of myocardial infarction
[61, 62]. This eﬀect was associated with decreased expression
of ACE and Ang II and increased expression of Ang-(1–
7) [62]. Collectively, these observations reveal that ACE2
eﬀectively plays a protective role in the cardiac structure and
function.
Since the discovery of Ang-(1–7) in the late 1980s [63,
64], several studies have demonstrated important eﬀects
of this peptide in hearts. The presence of Ang-(1–7) and
its receptor Mas in the heart [65, 66] and the ability of
this organ to produce Ang-(1–7) [55, 67]a r ee v i d e n c e s
of the role of this peptide in cardiac tissues. Functionally,
Ang-(1–7) induces an antiarrhythmogenic eﬀect against
ischemia/reperfusion injuries in rats [17, 68]a sw e l la s
prevents atrial tachycardia and ﬁbrillation in rats and dogs
[69, 70]. Treatment with Ang-(1–7) improved the coronary
perfusion and cardiac function in rats after myocardial
infarction [71] and after ischemia/reperfusion injury [72].
Increases in circulating Ang-(1–7) levels in transgenic rats
reduced the cardiac hypertrophy [17]a n dﬁ b r o s i s[ 20,
22] induced by isoproterenol administration. These eﬀects
are apparently independent of changes in blood pressure
since Grobe and colleagues [18] have demonstrated that
the antiﬁbrotic and antihypertrophic actions of Ang-(1–
7) are still observed in Ang-II-infused hypertensive rats.
Local overexpression of Ang-(1–7) in hearts of mice and
rats improved the myocardial contractility and prevented the
isoproterenol- and hypertension-induced cardiac remodel-
ing [19, 21]. Altogether, these ﬁndings support a direct eﬀect
of Ang-(1-7) in the heart.
Further evidence for the role of Ang-(1–7)/Mas in the
pathophysiology of the heart came from experimental pro-
tocols utilizing mice with genetic deﬁciency of Mas. They
revealed that the cardiac function is impaired in Mas knock-
out mice likely due to the increased extracellular matrix
proteins deposition in the heart [66, 73]. This proﬁbrotic
phenotype may be related to changes in matrix metallopro-
teinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) levels and/or activities [74, 75].
Although further elucidations regarding the signaling
pathways involved in Mas activation are necessary, some
mechanisms have been proposed. Overexpression of Ang-
(1–7) in hearts of rats causes an improvement in the [Ca2+]
handling in cardiomyocytes and increases the expression of
SERCA2a [21]. In keeping with these results, cardiomyocytes
from Mas-deﬁcient mice present slower [Ca2+]i transients
accompanied by a lower Ca2+ ATPase expression in the
sarcoplasmic reticulum [66, 76]. Although acute Ang-(1–
7) treatment failed to alter Ca2+ handling in ventricular
myocytes of rats [76], these ﬁndings suggest an important
role of the Ang-(1–7)/Mas in the long-term maintenance of
the Ca2+ homeostasis in the heart.
One of the mechanisms by which Ang-(1–7) plays its
eﬀects in the heart is stimulating the nitric oxide (NO) pro-
duction. Indeed, it has been demonstrated that Ang-(1–7)
via Mas increases the synthesis of NO through a mechanism
involving the activation of the endothelial NO synthase
(eNOS). These eﬀects were abolished by A-779 and are
absent in cardiomyocytes from Mas-deﬁcient mice [76].
Recently, Gomes et al. [77] found that the treatment of
isolated cardiomyocytes of rats with Ang-(1–7) eﬃciently
prevents the Ang-II-induced hypertrophy by modulating
the calcineurin/NFAT signaling cascade. These eﬀects were
blocked by NO synthase inhibition and by guanylyl cyclase
inhibitors, indicating that these eﬀects are mediated by the
NO/cGMP pathway.
Also, Ang-(1–7) inhibits serum-stimulated mitogen-ac-
tivated protein kinase (MAPK) activation in cardiac my-
ocytes [78] and prevents the Ang-II-mediated phospho-
rylation of ERK1/2 and Rho kinase in hearts in a dose-
dependent manner [79]. In line with these data, activation of
endogenousACE2signiﬁcantlyreducedthephosphorylation
of ERK1/2 in hearts of hypertensive rats (SHRs) [48].
However, Mercure et al. [19] reported that overexpression
of Ang-(1–7) in hearts of rats decreases the Ang-II-induced
phosphorylation of c-Src and p38 kinase, whereas the
increase in ERK1/2 phosphorylation was unaﬀected by the
expression of the transgene, thereby suggesting a selective
eﬀect of Ang-(1–7) on intracellular signaling pathways
related to cardiac remodeling.
Overall, these data reveal a key role of the ACE2/Ang-(1–
7)/Mas axis in the pathophysiology of the cardiac structure
and function. Activation of this axis might be an important
strategy to develop a new generation of cardiovascular ther-
apeutic agents against cardiac dysfunction and pathological
remodeling of the heart.4 International Journal of Hypertension
3.VascularACE2/Ang-(1–7)/MasAxis
Early studies have reported the endothelium as the major
site for generation [67] and metabolism [41]o fA n g - ( 1 –
7). In addition to Ang-(1–7), endothelial cells also express
ACE2 and Mas [80, 81]. Thus, now it is recognized that the
ACE2/Ang-(1–7)/Mas axis is present in vascular endothelial
cells and modulates its function promoting vasorelaxation
[82], reduction of the oxidative stress [83, 84], and antipro-
liferative eﬀects [85, 86].
The vasodilatory actions of Ang-(1–7) have been re-
ported in many studies in several vascular beds and prepa-
rations, including mouse [16, 23]a n dr a t[ 15] aortic rings,
canine [87] and porcine [88] coronary arteries, canine
middle cerebral artery [89], porcine piglet pial arterioles
[90],felinemesentericvascularbed[91],rabbitrenalaﬀerent
arterioles [92], and mesenteric microvessels of normotensive
[93] and hypertensive [94] rats. Vascular Ang-(1–7) actions
are still controversial in human. For example, it has been
shown that Ang-(1–7) causes vasodilation in forearm circu-
lation of normotensive subjects and patients with essential
hypertension [95] while other studies were unable to report
any signiﬁcant eﬀect of Ang-(1–7) in the same vascular
territory in ACEi-treated patients [43].
The Mas receptor is critically involved in the vascular
eﬀects of Ang-(1–7). In fact, many of these actions are com-
pletely abolished by A-779 or partially blocked by this antag-
onist [3, 86, 96]. Importantly, the endothelium-dependent
relaxation induced by Ang-(1–7) in mouse aortic rings is
absent in vessels derived from Mas-knockout mice [16].
However, other studies have shown that Ang-(1–7) also
interacts with ACE, AT1,a n dA T 2-like receptors, suggesting
the existence of additional sites of interaction for Ang-(1–7)
[3, 97, 98]. Indeed, Silva et al. [99] reported evidence for the
presence of a distinct subtype of Ang-(1–7) receptor sensible
to D-pro7-Ang-(1–7), a second Mas antagonist, but not to
A-779 in aortas of Sprague-Dawley rats.
The vascular eﬀects of Ang-(1–7) are endothelium
dependent and involve the production of vasodilator prod-
ucts, such as prostanoids, NO, and endothelium-derived
hyperpolarizing factor (EDHF) [16, 81, 100]. Pinheiro
and coworkers [101] found that Ang-(1–7) promotes an
increase in NO release in Mas-transfected chinese hamster
ovary (CHO) cells [101]. Furthermore, short-term infu-
sion of Ang-(1–7) improved the endothelial function by
a mechanism involving NO release in rats [102]. Mas
deletion resulted in endothelial dysfunction associated with
an unbalance between NO and oxidative stress [83]. Also,
Mas activation by Ang-(1–7) in human endothelial cells
stimulated eNOS phosphorylation/activation via the Akt-
dependent pathway [81]. Other mechanisms appear to be
involved in the Ang-(1–7) vascular actions. Roks et al. [103]
have shown that Ang-(1–7) inhibits the vasoconstriction
induced by Ang II in human internal mammary arteries,
thereby suggesting that Ang-(1–7) can regulate the Ang II
eﬀects [103]. In fact, Ang-(1–7) negatively modulates the
Ang II type 1 receptor-mediated activation of c-Src, and its
downstream targets ERK1/2 and NAD(P)H oxidase [104].
The counterregulatory action of Ang-(1–7) on Ang II
signaling has been also observed in cardiomyocytes [77],
vascular smooth muscle cells [105], and ﬁbroblasts [106].
Additionally, an interaction between Mas and bradykinin
(Bk) type 2 (B2) receptors may modulate some of the Ang-
(1–7) eﬀects in blood vessels [107]. Indeed, it has been
demonstratedthatAng-(1–7)potentiatesthevasodilatorand
hypotensive eﬀects of Bk in several vascular beds [93, 108–
110].
As the major enzyme involved in Ang-(1–7) formation,
ACE2 has also a crucial role in vessels. Lovren et al. [111]
have demonstrated that ACE2 ameliorates the endothelial
homeostasis via a mechanism involving reduction of the
reactive oxygen species production [111]. Of note, this eﬀect
was attenuated by A-779 [111]. Moreover, overexpression of
ACE2 in vessels of hypertensive rats resulted in reduction
in the arterial blood pressure and improvement of the
endothelial function associated with increased circulating
Ang-(1–7) levels [112]. Overall, these data indicate that the
beneﬁcial eﬀects of ACE2 are, at least in part, mediated by
Ang-(1–7). Recently, we have demonstrated that activation
of endogenous ACE2 causes a dose-dependent hypotensive
eﬀect in normotensive and hypertensive rats [113]. Also,
the response to Bk administration was augmented in rats
chronicallytreatedwithXNT,anACE2activator[113].How-
ever, we were unable to demonstrate any signiﬁcant eﬀect of
XNT on blood pressure in response to the administration
of Ang II or Losartan in normotensive and hypertensive rats
(Figure 2).
4. Pulmonary ACE2/Ang-(1–7)/MasAxis
In the past few years, the participation of the ACE2/Ang-
(1–7)/Mas axis in the establishment and progression of pul-
monary diseases has become evident. Indeed, the important
role of the RAS in the lung pathophysiology and the side
eﬀects and pulmonary toxicity induced by the ACEi raised
the interest to evaluate the activation of the ACE2/Ang-
(1–7)/Mas axis as an alternative target to treat pulmonary
pathologies. Thus, it has been reported beneﬁcial outcomes
induced by the activation of this axis in animal models
of acute respiratory distress syndrome (ARDS), pulmonary
hypertension (PH), ﬁbrosis, and lung cancer [31, 37, 114–
117]. These studies pointed out that the imbalance between
the ACE/Ang II/AT1 and the ACE2/Ang-(1–7)/Mas axes of
the RAS might be relevant in lung diseases. Taking into
accountthatsystemichypotensionisanimportantlimitation
totheuseofACEiandARBsinpulmonarypatients,therapies
based on the ACE2/Ang-(1–7)/Mas axis emerge as a safe
and eﬃcient approach since studies using the ACE2 activator
XNT or ACE2 gene transfer have shown that these strategies
induce beneﬁcial pulmonary outcome without changes in
systemic blood pressure in rats and mice [39, 117, 118].
Imai and colleagues [37] demonstrated the role of ACE2
in ARDS pathogenesis. They found that a more severe ARDS
was reached in ACE2 knockout mice, and this phenotype
was reversed by double genetic deletion of the ACE2 and
ACE genes or by the treatment with recombinant human
ACE2 (rhACE2). Furthermore, Ang II levels were relatedInternational Journal of Hypertension 5
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Figure 2: Eﬀects of Ang II and Losartan on arterial blood pressure of rats chronically treated with XNT. The responses to increasing doses
of Ang II were similar in vehicle- and XNT-treated (a) normotensive (Wistar-Kyoto rats—WKY) and (b) hypertensive (spontaneously
hypertensive rats—SHR) rats. Likewise, the response to Losartan (0.25mg/kg) was similar in vehicle- and XNT-treated (c) normotensive
(WKY) and (d) hypertensive (SHRs) rats. The blood pressure was measured through a catheter inserted into the carotid artery and Ang II
and Losartan were administrated in bolus using the jugular vein.
to the severity of the lung injury. Of note, ACE2 is widely
expressed in the pulmonary endothelium, vasculature, and
pneumocytes[119,120].Also,rhACE2inhibitedtheincrease
ofAngIIandTNF-αlevels,attenuatedthearterialhypoxemia
and PH, and ameliorated the distribution of the pulmonary
blood ﬂow in lipopolysaccharide-induced lung injury in
piglets [121]. Therefore, these studies suggest that ACE2 is a
suitable target to arrest the development of ARDS in patients
at risk.
The stimulation of the ACE2/Ang-(1–7)/Mas axis has
been successful used to prevent and reverse PH and ﬁbrosis
in animals. ACE2 activation using the compound XNT or
inductionofACE2overexpressionbygenetransfereﬃciently
prevented and, more importantly, reversed the increase of
the right systolic ventricular pressure (RSVP), pulmonary
ﬁbrosis, imbalance of the RAS, and inﬂammation in animals
(rats and mice) with PH induced by monocrotaline (MCT)
orinratswithpulmonaryﬁbrosiscausedbybleomycintreat-
ment [39, 117, 118]. In keeping with these ﬁndings, Ang-(1–
7) gene transfer into the lungs triggered similar protective
actions in MCT-treated rats [39]. In addition, Ang-(1–7)
via Mas prevented the apoptosis of alveolar epithelial cells
and the Jun N-terminal kinase (JNK) activation induced by
bleomycin [122]. The involvement of the Ang-(1–7)/Mas in
PH was further evidenced by the observation that the XNT
eﬀectsareblockedbyA-779[117].Furthermore,inbothlung
specimens from patients with idiopathic pulmonary ﬁbrosis
andfromanimalswithbleomycin-inducedpulmonaryﬁbro-
sis were reported a reduction in mRNA, protein, and activity
of ACE2 with a reciprocal increase in Ang II level [116].
A growing body of studies has focused on the relevance
of the ACE2/Ang-(1–7)/Mas axis in the pulmonary cancer
pathophysiology. The protein expression of ACE2 is reduced
in non-small-cell lung carcinoma (NSCLC) along with an
increase in Ang II levels. Moreover, overexpression of ACE2
in cultured A549 lung cancer cells and in human lung
cancer xenografs inhibited the cell growth and the vascular
endothelial growth factor-a (VEGFa) expression induced by
Ang II [123, 124]. Gallagher and Tallant [125] evaluated the6 International Journal of Hypertension
eﬀects of several angiotensin peptides [Ang I, Ang II, Ang-
(2–8), Ang-(3–8), and Ang-(3–7)] in SK-LU-1 cancer cells
growth, and only Ang-(1–7) showed signiﬁcant attenuation
of the DNA synthesis and proliferation. The antiproliferative
eﬀect of Ang-(1–7) was mediated by its receptor Mas and
inhibition of the ERK1/2 pathway. Neither the blockage of
AT1 norAT2 succeededininhibitingtheactionofAng-(1–7).
Inkeepingwiththesedata,theantiproliferativeeﬀectofAng-
(1–7) was observed in human A549 lung tumor xenograft
growth along with a marked decrease in the vessel density
in mice through a mechanism involving cyclooxygenase-2
(COX-2) [126, 127]. Of note, in a nonrandomized phase I
clinical trial conducted by Petty and colleagues [38], sub-
cutaneous injections of Ang-(1–7) were administered in 18
patients with advanced solid tumors refractory to standard
therapy. Despite the mild adverse eﬀects observed with the
Ang-(1–7) treatment, generally it was well tolerated. There
were no treatment-related deaths. Clinical beneﬁts were
observed in 27% of the patients. Altogether, these studies
provide insights into the involvement of the ACE2/Ang-(1–
7)/Mas axis in lung cancer.
5. Pharmacological Therapeutic Strategies
Basedon theACE2/Ang-(1–7)/MasAxis
Many advances have been achieved regarding the ther-
apeutic regulation of the RAS. Current therapies based
on the modulation of the RAS include the ACEi, ARBs,
and renin inhibitors. In general, these drugs prevent or
reverse endothelial dysfunction and atherosclerosis, reduce
cardiovascular mortality and morbidity of patients with
coronary artery disease, and hold antihypertensive eﬀects
[128].
Classically, the mechanisms of action of the ACEi and
ARBs involve the blockade of the synthesis and actions of
Ang II, respectively. However, the RAS is a complex hor-
monal system and, consequently, other mechanisms are
likely implicated in the actions of these drugs [42, 86, 129].
They cause substantial increase in plasma levels of Ang-(1–
7), leading to the assumption that their clinical eﬀects might
be partly mediated by this heptapeptide [42, 130]. Indeed, a
variety of eﬀects of the ACEi and ARBs can be abolished or
attenuated by Mas antagonism, conﬁrming the role of Ang-
(1–7) in the actions of these compounds [129, 131]. The
beneﬁcialeﬀectsofAng-(1–7)aswellasitslikelyinvolvement
in the eﬀects of the ACEi and ARBs represent a strong
evidence for the therapeutic potential of the activation of the
ACE2/Ang-(1–7)/Mas axis (Figure 3).
5.1. Ang-(1–7) Formulations. The beneﬁcial eﬀects of Ang-
(1–7) are well known; however, the therapeutic utilization of
thispeptideislimitedduetoitsunfavorablepharmacokinetic
properties. Ang-(1–7) has a short half-life (approximately
10 seconds) since it is rapidly cleaved by peptidases [132].
Furthermore, Ang-(1–7) is degraded during its passage
through the gastrointestinal tract when orally administrated.
Thus, new strategies are crucial to make feasible the clinical
application of Ang-(1–7).
Recently, a formulation based on the Ang-(1–7) included
into hydroxypropyl β-cyclodextrin [HPβCD/Ang-(1–7)] was
developed by Lula and colleagues [133]. Cyclodextrins are
pharmaceutical tools used for design and evaluation of
drug formulations, and they enhance the drug stability
and absorption across biological barriers and oﬀer gastric
protection [134]. The amphiphilic character of cyclodex-
trins allows the possibility of formation of supramolecular
inclusion complexes stabilized by noncovalent interactions
with a variety of guest molecules [133, 134]. In this regard,
the formulation HPβCD/Ang-(1–7) allowed the oral admin-
istration of Ang-(1–7). Pharmacokinetic and functional
studies showed that oral HPβCD/Ang-(1–7) administration
signiﬁcantly increases plasma Ang-(1–7) levels and pro-
motes an antithrombotic eﬀect that was blunted in Mas
deﬁcient mice [135]. Marques and colleagues [136]h a v e
found that chronic oral administration of HPβCD/Ang-(1–
7)signiﬁcantlyattenuatestheheartfunctionimpairmentand
cardiac remodeling induced by isoproterenol treatment and
myocardial infarction in rats [136].
In addition, liposomal delivery systems represent an
alternative method to administer Ang-(1–7) [137]. Admin-
istration of liposomes containing Ang-(1–7) in rats led to
prolonged hypotensive eﬀect for several days in contrast
to the response observed when the free peptide was used
[137, 138].
A strategy used to protect the Ang-(1–7) against prote-
olytic degradation was proposed by Kluskens and coworkers
[139]. Using the ability of prokaryotes to cyclize peptides,
they synthesized a cyclic Ang-(1–7) derivative [thioether-
bridged Ang-(1–7)] which presented an increased stability in
homogenates of diﬀerent organs and plasma and enhanced
the Ang-(1–7) bioavailability in rats [139]. Furthermore,
cyclized Ang-(1–7) induced a relaxation in precontracted
aorta rings of rats which was blocked by the Ang-(1–7)
receptor antagonist D-Pro7-Ang-(1–7), providing evidence
that cyclized Ang-(1–7) also interacts with Mas [139].
5.2. Synthetic Mas Receptor Agonists. AVE 0991 was the ﬁrst
nonpeptide synthetic compound developed with the inten-
tionofstimulatingtheMasreceptor.Thiscompoundmimics
the Ang-(1–7) eﬀects in several organs such as vessels [140,
141], kidney [101], and heart [142, 143]. Similar to Ang-
(1–7), AVE 0991 induced a vasodilation eﬀect which was
absent in aortic rings of Mas-deﬁcient mice [140]. Moreover,
its eﬀects in aortic rings were blocked by the two Ang-(1–
7) receptor antagonists, A-779 and D-Pro7-Ang-(1–7) [140].
AVE0991potentiatedtheacetylcholine-inducedvasodilation
in conscious normotensive rats, and this eﬀect was abolished
by A-779 and L-NAME [102]. Similarly, it was able to
increase the hypotensive eﬀect of Bk in normotensive rats,
and A-779 also blocked this eﬀect [107]. Ferreira et al.
[142, 143] reported that AVE 0991 protects the heart against
cardiac dysfunction and remodeling caused by isoproterenol
treatment or by myocardial infarction in rats [142, 143]. In
Mas-transfected cells, AVE 0991 induced NO release which
was blunted by A-779 and not by AT2 or AT1 antagonists
[101]. All these data support the concept that AVE 0991 isInternational Journal of Hypertension 7
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an Ang-(1–7) mimetic and that its actions are mediated by
the interaction with Mas.
Using a computational discovery platform for predicting
novel naturally occurring peptides that may activate GPCR,
two novel peptides, designated as CGEN-856 and CGEN-
857, with amino acid sequence unrelated to angiotensin
peptides, were found to display high speciﬁcity for Mas [23].
These peptides elicited Ca+2 inﬂux in CHO cells overex-
pressing Mas without any activity in AT1 or AT2 receptors
[144]. CGEN-856S, a derivative of the CGEN-856 peptide,
induced beneﬁcial cardiovascular eﬀects similar to those
caused by Ang-(1–7) [23]. This compound competes with
Ang-(1–7) for the same bind site in Mas-transfected cells.
Furthermore, similar to Ang-(1–7), CGEN-856S produced a
vasodilation eﬀect which was absence in Mas-deﬁcient mice,
indicating that this compound also acts via Mas [23]. This
was conﬁrmed by the inhibition of the CGEN-856S eﬀects
by the Mas antagonist A-779. Importantly, Savergnini et al.
[23] showed that CGEN-856S promotes antiarrhythmogenic
eﬀects and produces a small dose-dependent decrease in
arterial pressure of conscious SHR [23].
5.3. ACE2 Activators. A new approach addressing the ther-
apeutic potential of the activation of the ACE2/Ang-(1–
7)/Mas axis was proposed by Hern´ andez Prada et al.
[113]. Based on the crystal structure of ACE2 and using a
virtual screening strategy, it was identiﬁed small molecules
that may interact with this enzyme leading to changes in
its conformation and, consequently, enhancing its activity
[113]. Thus, the ACE2 activator, namely XNT, was identiﬁed
and its administration in SHR decreased blood pressure,
induced an improvement in cardiac function, and reversed
the myocardial and perivascular ﬁbrosis observed in these
animals [48, 113]. The beneﬁcial eﬀects of XNT were also8 International Journal of Hypertension
observed in rats with PH induced by MCT [117]. Further-
more, this compound attenuated the thrombus formation
andreducedtheplateletattachmenttovesselsinhypertensive
rats [145].
It appears that the pharmacological activation of ACE2
promotes its beneﬁcial eﬀects due to an increased Ang-(1–7)
production with concomitant degradation of Ang II. In fact,
coadministration of A-779 abolished the protective eﬀects
of XNT on PH [117]. In addition, the antiﬁbrotic eﬀect of
XNTobservedinheartsofSHRwasassociatedwithincreases
in cardiac Ang-(1–7) expression [48]. However, it is also
pertinent to point out that oﬀ-target eﬀects of XNT on these
beneﬁcial outcomes cannot be ruled out at the present time.
6. Conclusions
The complexity of the RAS is far beyond we could suspect
few years ago. There is growing evidence that changes in
the novel components of the RAS [Ang-(1–7), ACE2, and
Mas] may take part of the establishment and progression of
cardiovascular and respiratory diseases. Importantly, these
new components of the RAS, due to their counter regulatory
actions, are candidates to serve as a concept to develop new
cardiovascular and respiratory drugs.
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